All In Biotech

Drug Trial Radar · NCT02278341

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis

Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 838 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

838

Actual

Start

Nov 21, 2014

Primary completion

Jun 8, 2017

Study completion Jul 6, 2018

Sponsor

Lead sponsor
Astellas Pharma Europe B.V.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Kyntra Bio
First posted
Oct 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was conducted to explore a new therapy for anemia in participants with end stage renal disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin (which contains iron) is important for the transport of oxygen in your blood. The purpose of this study was to evaluate if roxadustat is effective and safe in the maintenance treatment of anemia in ESRD participants on stable dialysis. Roxadustat was compared to epoetin alfa and darbepoetin alfa, commercially available medicines for treatment of anemia.

Conditions

  • Anemia
  • End Stage Renal Disease (ESRD)

Interventions

  • RoxadustatDrug

    Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.

  • Epoetin alfaDrug

    Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.

  • Darbepoetin alfaDrug

    Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.

  • IronDrug

    Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)]Time frame: Baseline and weeks 28 to 36
  2. Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)]Time frame: Baseline and weeks 28 to 52

Locations

143 sites in 17 countries. Site status is shown where the registry gives one.

  • Site BE32001

    Aalst, Belgium

  • Site BE32019

    Antwerp, Belgium

  • Site BE32002

    Antwerp, Belgium

  • Site BE32012

    Baudour, Belgium

  • Site BE32017

    Bonheiden, Belgium

  • Site BE32003

    Leuven, Belgium

  • Site BE32013

    Liège, Belgium

  • Site BE32011

    Roeselare, Belgium

  • Site BE32004

    Brussels, Flemish Brabant, Belgium

  • Site BG35925

    Blagoevgrad, Bulgaria

  • Site BG35931

    Haskovo, Bulgaria

  • Site BG35915

    Pleven, Bulgaria

  • Site BG35909

    Plovdiv, Bulgaria

  • Site BG35919

    Plovdiv, Bulgaria

  • Site BG35920

    Rousse, Bulgaria

  • Site BG35938

    Shumen, Bulgaria

  • Site BG35924

    Sofia, Bulgaria

  • Site BG35906

    Sofia, Bulgaria

  • Site BG35921

    Sofia, Bulgaria

  • Site BG35907

    Stara Zagora, Bulgaria

  • Site BG35916

    Varna, Bulgaria

  • Site BG35918

    Varna, Bulgaria

  • Site BG35903

    Veliko Tarnovo, Bulgaria

  • Site BG35937

    Yambol, Bulgaria

  • Site HR38508

    Čakovec, Croatia

  • Site HR38505

    Karlovac, Croatia

  • Site HR38507

    Osijek, Croatia

  • Site HR38506

    Rijeka, Croatia

  • Site HR38504

    Slavonski Brod, Croatia

  • Site HR38501

    Zadar, Croatia

  • Site HR38509

    Zagreb, City of Zagreb, Croatia

  • Site CZ42008

    Liberec, Czechia

  • Site CZ42021

    Prague, Czechia

  • Site CZ42015

    Rakovník, Czechia

  • Site FR33005

    Amiens, France

  • Site FR33010

    La Tronche, France

  • Site FR33007

    Saint Priez En Jarez, France

  • Site FR33055

    Saint-Ouen, France

  • Site FR33056

    Valenciennes, France

  • Site GE99503

    Tbilisi, Georgia

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.